Psychedelic Spotlight News

MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)

MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/

Follow us on Twitter:
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
Stay tuned for more updates!

In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.

MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.

Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.

The results were very positive, though perhaps not paradigm shifting — yet.

The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.

The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.

Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.

Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”

In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”

Interested in reading the article? Click here: 👇

MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/

#MindMed #Anxiety #MNMD

End of content

End of content